Skip to content

MERIFEIM Standard and MERIFEIM No-Touch Pack (Standard) are a rectangular block of Absorbable Gelatin Sponge U.S.P

MERIFEIM(TM) Standard and MERIFEIM(TM) Standard (No-Touch Pack)-PMCF Study: A prospective, observational, single-arm, open-label, multi-centre, post-market clinical follow-up study to evaluate the Safety and Performance of the MERIFEIM(TM) Standard and MERIFEIM(TM) Standard (No-Touch Pack) Absorbable Gelatin Sponge U.S.P. in a real-world setting - NIL

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/092810
Enrollment
70
Registered
2025-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Meril Life Sciences Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.The Subject of age 18 and above, irrespective of gender willing to undergo intervention with Merifeim. 2. The Subject is willing and able to provide written Informed Consent by signing and dating the IRB or EC-approved Informed Consent form. 3.In the case of a Subject and LAR being illiterate, a literate impartial witness is required during consenting. 4. Subjects with the absence of any prior surgical interventions at the designated site. 5. Subjects with the absence of active bleeding preoperatively, as determined by clinical symptoms, vital signs, and laboratory examination findings. 6. The Subject is willing and able to comply with postoperative scheduled clinical evaluations. 7. Subjects who are able to give voluntary, written informed consent to participate in this PMCF and from whom consent has been obtained

Exclusion criteria

Exclusion criteria: 1. Subjects undergoing closure of skin incisions will be excluded, because it may interfere with the healing of skin edges. 2. Subjects with known allergies to collagen. 3. Subjects undergoing treatment in intravascular compartments will be excluded due to the risk of embolization. 4. If subject have any infected wounds or wounds with an inflammatory secretion. 5. If subject has any infection. 6. Subjects treating with methyl methacrylate adhesives, autologous blood salvage circuits.

Design outcomes

Primary

MeasureTime frame
1.Time to Hemostasis 2.Device-related Adverse events 3.Success rateTimepoint: 1.Time Frame: Intra-operative 2.Time Frame: Post operative 7days, 15days and 1 month 3.Time Frame: up to 6 minutes post procedure

Secondary

MeasureTime frame
1.Intra-operative Blood Loss 2.Post-operative pain score 3.Length of hospital stay 4.Ease of handlingTimepoint: 1.Time Frame: Intra-operative 2.Time Frame: Post-operative 7 days, 15days & 1 month 3.Time Frame: From admission to discharge 4.Time Frame: Intra-operative

Countries

India

Contacts

Public ContactDr Kirankumar Shetty

Meril Life Sciences Pvt. Ltd

kirankumar.shetty@merillife.com9743700109

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026